BioNTech SE (NASDAQ: BNTX) reported Q3 EPS of EUR0.67, EUR0.05 better than the analyst estimate of EUR0.62. Revenue for the quarter came in at EUR895.3 million versus the consensus estimate of EUR837.61 million.

GUIDANCE:

Updated 2023 COVID-19 vaccine revenue guidance of around EUR4 billion, versus EUR5 billion prior.

For earnings history and earnings-related data on BioNTech SE (BNTX) click here.